We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+8.65%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$6.63B
AUM Growth
+$825M
Cap. Flow
+$30.6M
Cap. Flow %
0.46%
Top 10 Hldgs %
82.61%
Holding
140
New
29
Increased
38
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.1M
2
INCY icon
Incyte
INCY
+$10.5M
3
DNLI icon
Denali Therapeutics
DNLI
+$8.99M
4
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$7.86M
5
ALBO
Albireo Pharma Inc
ALBO
+$7.61M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$33.5M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.4M
3
RXDX
Ignyta, Inc.
RXDX
+$11.1M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$10.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.07M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.26%
2 Consumer Discretionary 19.67%
3 Miscellaneous 18.89%
4 Healthcare 18.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
26
CALL
Incyte
INCY
$24.8B
$23.7M 0.36%
250,000
+100,000
+67% +$10.5M
FOLD
27
CALL
DELISTED
Amicus Therapeutics
FOLD
$20.1M 0.3%
1,400,000
+400,000
+40% +$5.5M
NBIX icon
28
Neurocrine Biosciences
NBIX
$16B
$19.4M 0.29%
250,000
-150,000
-38% -$10.2M
ARRY
29
DELISTED
Array Biopharma Inc
ARRY
$19.2M 0.29%
1,500,000
– –
MDCO
30
CALL
DELISTED
Medicines Co
MDCO
$19.1M 0.29%
700,000
+500,000
+250% +$15.4M
REGN icon
31
CALL
Regeneron Pharmaceuticals
REGN
$81.7B
$18.8M 0.28%
+50,000
New +$20.2M
ATRA icon
32
Atara Biotherapeutics
ATRA
$94.2M
$18.1M 0.27%
40,000
+16,000
+67% +$5.91M
BHF icon
33
CALL
Brighthouse Financial
BHF
$2.88B
$17.6M 0.27%
+300,000
New +$17.7M
AMGN icon
34
CALL
Amgen
AMGN
$206B
$17.4M 0.26%
100,000
– –
AVXS
35
DELISTED
AveXis, Inc. Common Stock
AVXS
$16.6M 0.25%
150,000
+30,000
+25% +$3.01M
JUNO
36
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$16M 0.24%
350,000
+150,000
+75% +$7.48M
CELG
37
CALL
DELISTED
Celgene Corp
CELG
$15.7M 0.24%
+150,000
New +$16.9M
ANAB icon
38
AnaptysBio
ANAB
$1.6B
$15.1M 0.23%
150,000
– –
FOLD
39
DELISTED
Amicus Therapeutics
FOLD
$14.4M 0.22%
1,000,000
+300,000
+43% +$4.12M
GBT
40
DELISTED
Global Blood Therapeutics, Inc.
GBT
$13.8M 0.21%
350,000
+50,000
+17% +$1.87M
AXDX
41
DELISTED
Accelerate Diagnostics
AXDX
$13.1M 0.2%
50,000
+30,000
+150% +$7.03M
RDUS
42
DELISTED
Radius Health, Inc.
RDUS
$12.7M 0.19%
400,000
+150,000
+60% +$4.71M
MET icon
43
CALL
MetLife
MET
$61.7B
$12.6M 0.19%
250,000
-150,000
-38% -$7.9M
ARGX icon
44
argenx
ARGX
$61.6B
$12.6M 0.19%
200,000
+145,663
+268% +$4.77M
SAGE
45
DELISTED
Sage Therapeutics
SAGE
$12.4M 0.19%
75,000
-75,000
-50% -$7.27M
CLVS
46
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$10.2M 0.15%
+150,000
New +$10.5M
BMRN icon
47
CALL
BioMarin Pharmaceuticals
BMRN
$12.9B
$8.92M 0.13%
100,000
– –
BLUE
48
CALL
DELISTED
bluebird bio
BLUE
$8.9M 0.13%
3,860
– –
RGNX icon
49
Regenxbio
RGNX
$563M
$8.31M 0.13%
250,000
+90,000
+56% +$2.71M
TSRO
50
DELISTED
TESARO, Inc.
TSRO
$8.29M 0.13%
100,000
+25,000
+33% +$2.45M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2017 Portfolio in Review

As of Q4 2017, Artal Group held 140 positions worth $6.63B, up 14% from $5.81B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group's Q4 2017 filing shows 29 new, 38 increased, 20 reduced and 21 closed positions. Its largest new stake was Denali Therapeutics: 500,000 shares worth $7.82M. The largest sale was Nektar Therapeutics, an estimated $33.5M.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q4 2017 buy was Denali Therapeutics: 500,000 shares worth $7.82M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q4 2017, an estimated $25.1M increase.
  • Artal Group's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $33.5M.
  • Artal Group fully exited BioMarin Pharmaceuticals in Q4 2017, selling an estimated $17.4M.
  • Artal Group's ten largest holdings make up 83% of its $6.63B portfolio in Q4 2017.
  • Artal Group opened 29 new positions and closed 21 in Q4 2017.
  • Artal Group's portfolio value rose 14% quarter-over-quarter to $6.63B.

Based on Artal Group's 13F filing for Q4 2017, filed 9 Feb 2018.